Abstract
The Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics
report provides comprehensive understanding and unprecedented access to the
merger and acquisition (M&A) agreements entered into by the worlds leading
biopharma companies.
Fully revised and updated, the report provides details of merger and
acquisition agreements from 2003 to end 2008.
The report provides a detailed understand and analysis of how and why
companies enter merger and acquisition deals. The majority of deals are
acquisitions whereby the acquirer acquires the target company in a cash and/or
equity transaction.
Understanding the flexibility of a prospective partner' s negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 600 links to online copies of actual merger and
acquisition contract documents as submitted to the Securities Exchange
Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner' s flexibility on a wide range of important issues, many of
which will have a significant impact on each party' s ability to derive value
from the deal.
The initial chapters of this report provide an orientation of merger and
acquisition dealmaking and business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an analysis of the
trends in mergers and acquisitions as well as a discussion on the merits of
each type of deal.
Chapter 3 provides an overview of the structure of merger and acquisition
deals. The chapter includes numerous case studies to enable understanding of
both pure merger/acquisition deals and multicomponent deals where acquisition
forms a part.
Chapter 4 provides a review of the leading M&A deals since 2000. Deals are
listed by headline value, signed by bigpharma, most active bigpharma, and most
active of all biopharma companies. Where the deal has an agreement contract
published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary including M&A frequency and acquired companies since 2000
followed by a comprehensive listing of M&A contract documents available in the
public domain. Each deal title links via Weblink to an online version of the
actual contract document, providing easy access to each contract document on
demand.
Chapter 6 provides a comprehensive listing of all merger and acquisition
agreement contracts available in the public domain, respectively. The chapter
is organized by A-Z company name. Each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each
contract document on demand.
| 
View Cart
